In the present paper, we reveal the first time that DFE exerts a promising anticancer activity on clinically related PCa cell lines, LNCaP androgen-dependent and C4-2 castration-resistant cells, through coordinated blockade of SREBP-1/FASN/lipogenesis and the AR axis. This evidence concerns the gene FASN and posterior cortical atrophy.